組蛋白去乙醯化酶抑制劑市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球組蛋白去乙醯化酶抑制劑市場價值為 13 億美元，預計 2025 年至 2034 年期間的複合年成長率為 7.7%。組蛋白去乙醯化酶 (HDAC) 抑制劑透過去除組蛋白中的乙醯基在改變基因表現方面發揮關鍵作用，從而影響與各種疾病相關的細胞機制。由於癌症、神經系統疾病和自體免疫疾病發病率的上升，市場正在穩步成長，這繼續增加了對有效 HDAC 抑制劑的需求。此外，藥物開發的不斷進步，加上監管部門的批准和標靶治療的創新，進一步加速了市場擴張。不斷增加對 HDAC 抑制劑在克服化療抗藥性和提高治療效果方面的作用的研究也推動了該行業的成長。此外，對生物技術和製藥研究的投資不斷增加，以及主要行業參與者之間的合作，預計將促進新型 HDAC 抑制劑療法的商業化。

HDAC抑制劑廣泛應用於腫瘤學、神經學、心血管疾病和自體免疫疾病。它們的應用對於晚期疾病患者尤其重要，因為它們通常在全身化療之前使用以最佳化治療結果。鑑於多發性骨髓瘤、T 細胞淋巴瘤和神經退化性疾病的盛行率不斷上升，對創新 HDAC 抑制劑的需求持續成長。此外，越來越多的臨床試驗致力於擴大 HDAC 抑制劑在癌症治療之外的治療應用，預計將在預測期內促進市場成長。

組蛋白去乙醯化酶抑制劑市場根據分銷管道進行分類，主要部分包括醫院藥房、零售藥局和電子商務。 2024 年，醫院藥局部門的收入為 8.307 億美元。這種優勢很大程度上歸因於需要持續監測患者並嚴格控制已批准的 HDAC 抑制劑的劑量。由於潛在的嚴重副作用和毒性風險，這些抑制劑通常在醫院環境中使用，這推動了該配銷通路的需求。配備先進腫瘤科和輸液中心的醫院仍然是 HDAC 抑制劑治療的首選地點，鞏固了該領域在市場上的領先地位。

預計 2025 年至 2034 年間，異羥肟酸衍生物領域將產生可觀的收入。異羥肟酸衍生物被公認為最有效的 HDAC 抑制劑之一，廣泛用於癌症治療。它們能夠抑制腫瘤生長並克服化療抗藥性，因此在腫瘤學中至關重要。隨著多發性骨髓瘤和 T 細胞淋巴瘤等癌症的發生率持續上升，預計對這些抑制劑的需求將激增。研究和臨床研究的進步進一步加強了它們在癌症治療中的作用，確保了市場的持續成長。

美國組蛋白去乙醯化酶抑制劑市場預計在 2025 年至 2034 年間實現顯著的收入成長。 FDA 等監管機構積極批准新的 HDAC 抑制劑，特別是那些被指定為孤兒藥、快速通道或優先審查的抑制劑，這有助於刺激市場擴張。此外，美國阿茲海默症患者病率的不斷上升，也提高了人們對 HDAC 抑制劑神經保護作用的興趣，進一步推動了市場需求。隨著國內領先的生物技術和製藥公司的強大影響力，HDAC 抑制劑療法的創新不斷推進，促進了整體市場的成長。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 癌症發生率上升
    • 拓展腫瘤學以外的應用
    • 不斷成長的研發投資和臨床試驗
    • 監理機關核准和孤兒藥認定
  • 產業陷阱與挑戰
    • 治療費用高
    • 毒性和副作用
• 成長潛力分析
• 監管格局
• 差距分析
• 專利分析
• 管道分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按藥物類別，2021 年至 2034 年

• 主要趨勢
• 異羥肟酸衍生物
• 環肽
• 苯甲醯胺類

第6章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 腫瘤學
• 神經病學
• 其他應用

第7章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 電子商務

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Bristol-Myers Squibb Company
• Chipscreen Bioscience
• ITF Therapeutics
• Merck & Co.
• Novartis
• Spectrum Pharmaceuticals
• Taizhou EOC Pharma

The Global Histone Deacetylase Inhibitors Market was valued at USD 1.3 billion in 2024 and is projected to expand at a CAGR of 7.7% between 2025 and 2034. Histone deacetylase (HDAC) inhibitors play a crucial role in modifying gene expression by removing acetyl groups from histones, thereby influencing cellular mechanisms linked to various diseases. The market is witnessing steady growth driven by the rising incidence of cancer, neurological disorders, and autoimmune diseases, which continue to increase the demand for effective HDAC inhibitors. Additionally, continuous advancements in drug development, coupled with regulatory approvals and targeted therapy innovations, further accelerate market expansion. Increasing research into HDAC inhibitors' role in overcoming chemotherapy resistance and enhancing treatment efficacy is also fueling industry growth. Moreover, the growing investment in biotechnology and pharmaceutical research, alongside collaborations between key industry players, is expected to enhance the commercialization of new HDAC inhibitor therapies.

HDAC inhibitors are widely utilized in oncology, neurology, cardiovascular diseases, and autoimmune conditions. Their application is particularly crucial for patients in advanced disease stages, as they are often administered prior to systemic chemotherapy to optimize treatment outcomes. Given the rising prevalence of multiple myeloma, T-cell lymphoma, and neurodegenerative diseases, the need for innovative HDAC inhibitors continues to grow. Furthermore, an increasing number of clinical trials focused on expanding therapeutic applications for HDAC inhibitors beyond cancer treatment is expected to contribute to market growth over the forecast period.

The histone deacetylase inhibitors market is categorized based on distribution channels, with key segments including hospital pharmacies, retail pharmacies, and e-commerce. In 2024, the hospital pharmacies segment accounted for USD 830.7 million in revenue. This dominance is largely attributed to the need for continuous patient monitoring and stringent dosage regulation associated with approved HDAC inhibitors. Due to the potential severity of side effects and toxicity risks, these inhibitors are often administered in hospital settings, which drives demand within this distribution channel. Hospitals equipped with advanced oncology and infusion centers remain the preferred sites for HDAC inhibitor treatments, reinforcing the segment's leading position in the market.

The hydroxamic acid derivatives segment is expected to generate substantial revenue from 2025 to 2034. Recognized as some of the most potent HDAC inhibitors, hydroxamic acid derivatives are extensively used in cancer therapies. Their ability to suppress tumor growth and overcome chemotherapy resistance makes them essential in oncology. As the prevalence of cancers such as multiple myeloma and T-cell lymphoma continues to rise, the demand for these inhibitors is projected to surge. Advancements in research and clinical studies further strengthen their role in cancer treatment, ensuring sustained market growth.

The U.S. Histone Deacetylase Inhibitors Market is poised to experience significant revenue growth between 2025 and 2034. Regulatory agencies such as the FDA actively approve new HDAC inhibitors, particularly those designated as orphan drugs, fast-tracked, or given priority review, which helps stimulate market expansion. Additionally, the increasing prevalence of Alzheimer's disease in the U.S. has heightened interest in the neuroprotective effects of HDAC inhibitors, further driving market demand. With a strong presence of leading biotechnology and pharmaceutical companies in the country, innovation in HDAC inhibitor therapies continues to advance, contributing to overall market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising cancer incidence
    • 3.2.1.2 Expanding applications beyond oncology
    • 3.2.1.3 Growing R&D investments and clinical trials
    • 3.2.1.4 Regulatory approvals and orphan drug designations
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Toxicity and side effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Gap analysis
• 3.6 Patent analysis
• 3.7 Pipeline analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Hydroxamic acid derivatives
• 5.3 Cyclic peptides
• 5.4 Benzamides

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oncology
• 6.3 Neurology
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Bristol-Myers Squibb Company
• 9.2 Chipscreen Bioscience
• 9.3 ITF Therapeutics
• 9.4 Merck & Co.
• 9.5 Novartis
• 9.6 Spectrum Pharmaceuticals
• 9.7 Taizhou EOC Pharma